Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00977262
Other study ID # NL2800108109
Secondary ID
Status Completed
Phase N/A
First received September 11, 2009
Last updated April 20, 2010
Start date October 2009
Est. completion date December 2009

Study information

Verified date April 2010
Source Wageningen University
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

The main objective is to elucidate the acute effects of an oral intake of either saturated, monounsaturated or polyunsaturated fatty acids on peripheral blood mononuclear cells (PBMC) whole genome expression of obese and type 2 diabetic obese subjects.


Description:

Consumption of high-fat diets can lead to postprandial dyslipidemia, impairment of endothelial function, activation of immune cells and changes in gene expression profiles of immune cells such as peripheral blood mononuclear cells (PBMC). Recently it was shown that postprandial gene expression profiles of PBMC and plasma triglyceride (TG) and free fatty acid (FFA) responses are dependent on the type of dietary fat consumed (i.e. saturated, monounsaturated and polyunsaturated). Since obese and diabetic subjects usually are in a pro-inflammatory state and have dyslipidemia and endothelial dysfunction we are interested in the effect of different fatty acids in a high load on the PBMC gene expression profiles, plasma cytokine profiles and endothelial function of these subjects.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria:

For all participants:

- male gender

- 50-70 yrs

For diabetic patients only:

- BMI >30 kg/m2

- Well-controlled diabetes: fasting plasma glucose concentration must be <10.0 mmol/l at the time of screening.

- Must be on sulphonylurea- or metformin therapy for at least 6 months with a constant dose for at least two months, or on dietary treatment for at least 6 months2.

For obese controls only:

- BMI > 30 kg/m2

- normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

For lean controls only:

- BMI 18-25 kg/m2

- normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

Exclusion Criteria:

For all participants:

- Female gender

- Age below 50 or above 70 years

- Hemoglobin levels <8.4 mmol/L

- Allergic to cow milk or dairy products

- Allergic to fish oil

- Vegetarian

- Tobacco smoker

- Current or recent (<4 weeks) use of fish oil supplements or more then four times fish/week; 24.35 g of EPA-DHA of fish per month (800 mg/day) as judged by the questionnaire.

- Received inoculations within 2 months of starting the study or planned to during the study

- Donated or intended to donate blood from 2 months before the study till two months after the study

- Unstable body weight (weight gain or loss > 3 kg in the past three months)

- Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, gastrointestinal disease, renal dysfunction)

- Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)

- abuse of drugs and/or alcohol

- participation in another biomedical study within 1 month before the first screening visit

For obese, type 2 diabetic subjects only:

- severe diabetes which requires application of insulin

- diabetes-related complications

For obese subjects and lean controls only:

- hyperglycemic according to WHO criteria (OGTT, fasting blood glucose >6.0mM, after 2 hr>11mM)

- systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg

- Urinary glucose concentrations (>0.25 g/l)

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)


Intervention

Other:
High saturated fat shake
milkshake containing 95 gram of fat, high percentage of saturated fat
High monounsaturated fat shake
milkshake containing 95 gram of fat, high percentage of monounsaturated fat
High polyunsaturated fat shake
milkshake containing 95 gram of fat, high percentage polyunsaturated fat

Locations

Country Name City State
Netherlands Wageningen University, Division of Human Nutrition Wageningen Gelderland
Netherlands Wageningen University, Division of Human Nutrition Wageningen

Sponsors (2)

Lead Sponsor Collaborator
Wageningen University Dutch Diabetes Research Foundation

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary PBMC gene expression profiles 0, 2, 4 hrs No
Secondary PBMC inflammatory response capacity 0, 2, 4 hrs No
Secondary Endothelial function 0, 2, 4 hrs No
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2